Literature DB >> 435685

Shape change of blood platelets--a model for cerebral 5-hydroxytryptamine receptors?

M Graf, A Pletscher.   

Abstract

1. In blood platelets of rabbits isolated by a stractan gradient and incubated in a protein-poor medium, tryptamine, 5-hydroxytryptamine (5-HT) and derivatives, quipazine and mescaline caused a shape change. This shape change was inhibited by low concentrations of methysergide. 2. The most potent antagonists of the 5-HT-induced shape change included ergoline derivatives and neuroleptic drugs, which showed high stereoselectivity. 3. (+)-Lysergic acid diethylamide ((+)-LSD), psilocine and some N',N'-dimethylated tryptamines acted as mixed agonist-antagonists. 4. The compounds found to be agonists or mixed agonist-antagonists on platelets have previously been shown to act also as 5-HT agonists in the central nervous system (CNS). 5. With regard to 5-HT antagonists, the 5-HT receptors of platelets reacted differently from those described earlier in brain areas with dense 5-hydroxytryptaminergic innervation, but showed similarities to 5-HT receptors investigated previously in spinal cord, cerebral cortex and possibly reticular formation. 6. It is concluded that platelets may be considered with caution as models for some, but not for all, 5-HT receptors in the CNS.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 435685      PMCID: PMC1668678          DOI: 10.1111/j.1476-5381.1979.tb07870.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  5-Methoxytryptamine: stimulation of 5-HT receptors mediating the rat hyperactivity syndrome and blood platelet aggregation.

Authors:  D J Boullin; A R Green
Journal:  Adv Biochem Psychopharmacol       Date:  1976

Review 2.  Platelets as models for monoaminergic neurons.

Authors:  A Pletscher
Journal:  Essays Neurochem Neuropharmacol       Date:  1978

3.  Characterization of receptors mediating 5-hydroxytryptamine- and catecholamine-induced platelet aggregation, assessed by the actions of alpha- and beta-blockers, butyrophenones, 5-HT antagonists and chlorpromazine.

Authors:  D J Boullin; P A Glenton
Journal:  Br J Pharmacol       Date:  1978-04       Impact factor: 8.739

4.  Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23,187.

Authors:  R L Kinlough-Rathbone; M A Packham; H J Reimers; J P Cazenave; J F Mustard
Journal:  J Lab Clin Med       Date:  1977-10

Review 5.  Serotonin receptors in the brain.

Authors:  H J Haigler; G K Aghajanian
Journal:  Fed Proc       Date:  1977-07

6.  Serotonergic component of neuroleptic receptors.

Authors:  J E Leysen; C J Niemegeers; J P Tollenaere; P M Laduron
Journal:  Nature       Date:  1978-03-09       Impact factor: 49.962

7.  Application of light-scattering theory to the optical effects associated with the morphology of blood platelets.

Authors:  P Latimer; G V Born; F Michal
Journal:  Arch Biochem Biophys       Date:  1977-04-15       Impact factor: 4.013

8.  Stimulus properties of phenethylamine hallucinogens and lysergic acid diethylamide: the role of 5-hydroxytryptamine.

Authors:  J C Winter
Journal:  J Pharmacol Exp Ther       Date:  1978-02       Impact factor: 4.030

9.  5-Hydroxytryptamine and dopamine transport by rat and human blood platelets.

Authors:  J L Gordon; H J Olverman
Journal:  Br J Pharmacol       Date:  1978-02       Impact factor: 8.739

10.  Effect of lisuride and other ergot derivatives on monoaminergic mechanisms in rat brain.

Authors:  W Kehr
Journal:  Eur J Pharmacol       Date:  1977-02-07       Impact factor: 4.432

View more
  14 in total

Review 1.  Platelets and neurobiological research.

Authors:  G V Born
Journal:  Experientia       Date:  1988-02-15

2.  Shape change of blood platelets brought about by myelin basic protein and other basic polypeptides.

Authors:  A Laubscher; A Pletscher; C G Honegger; J G Richards
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-12       Impact factor: 3.000

3.  Ca2+ as messenger of 5HT2-receptor stimulation in human blood platelets.

Authors:  H Affolter; P Erne; E Bürgisser; A Pletscher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-04       Impact factor: 3.000

4.  Platelet shape change in patients with psychiatric disorders and treated with phenothiazines, thioxanthines, butyrophenones, benzodiazepines, tricyclic antidepressants and beta-adrenergic blocking agents.

Authors:  D J Boullin
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

5.  Increases in aggregation by and uptake of 5-hydroxytryptamine with platelets from rabbits treated with chlorpromazine.

Authors:  M Baldacci; M Baldacci; T D Bergel; G V Born; M Hickman
Journal:  Br J Pharmacol       Date:  1980-05       Impact factor: 8.739

6.  Serotonin-induced decrease of intracellular Ca(2+) release in platelets of bulimic patients normalizes during treatment.

Authors:  Lars Wöckel; Florian Daniel Zepf; Sabrina Koch; Anikó-Eva Meyer-Keitel; Martin H Schmidt
Journal:  J Neural Transm (Vienna)       Date:  2008-12-10       Impact factor: 3.575

7.  Shape changes induced by biologically active peptides and nerve growth factor in blood platelets of rabbits.

Authors:  F Gudat; A Laubscher; U Otten; A Pletscher
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

8.  Human platelet function as a model for investigating the clinical efficacy of chlorpromazine.

Authors:  M B Youdim; A Hefez; B Oppenheim
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

9.  Rapid intracellular release of calcium in human platelets by stimulation of 5-HT2-receptors.

Authors:  P Erne; A Pletscher
Journal:  Br J Pharmacol       Date:  1985-02       Impact factor: 8.739

10.  The 5-hydroxytryptamine receptor of blood platelets.

Authors:  A Pletscher; H Affolter
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.